AUS
NZ
UK
CA
USA
IND
Highlights:
- The GILD stock added over 42 per cent in the running quarter.
- Gilead Sciences' revenue fell five per cent YoY in Q3 FY22.
- Revenue of Sirius XM Holdings Inc. (SIRI) rose four per cent YoY in Q3 FY22.
The Nasdaq 100 index comprises the biggest and most innovative firms in the US market. The 100 largest and most frequently traded American companies listed on the Nasdaq stock exchange make up the Nasdaq 100 Index.
Meanwhile, like all the indices, the Nasdaq 100 index also witnessed a sharp decline in 2022 due to the hovering market uncertainties.
The higher inflation, soaring interest rates, and other uncertainties had left the investors cold while forcing them to keep a distance from the risk-bet assets. So, today, we will be exploring two Nasdaq 100 stocks, which include Gilead Sciences, Inc. (NASDAQ:GILD) and Sirius XM Holdings Inc. (NASDAQ:SIRI), and their recent stock and financial performance.
Gilead Sciences, Inc. (NASDAQ:GILD)
The major biopharmaceutical firm, Gilead Sciences holds a dividend yield of 3.32 per cent. The firm's stock, which researches and develops antiviral drugs for treating HIV/AIDs, influenza, etc., surged nearly 21 per cent YTD and around 26 per cent YoY.
The GILD stock soared about 41 per cent in the last six months and its 52-week high was US$ 89.1 on December 5, 2022.
In Q3 FY22, Gilead Sciences Inc's revenue ticked down five per cent YoY to US$ 7 billion, while its diluted EPS was US$ 1.42, against US$ 2.05 in Q3 FY21. However, excluding Veklury, the company's overall product sales rose 11 per cent YoY to US$ 6.1 billion.
Sirius XM Holdings Inc. (NASDAQ:SIRI)
The communication services and broadcasting firm, Sirius XM Holdings Inc had a dividend yield of 1.57 per cent. The firm's stock, which offers satellite radio and online radio solutions in the US, surged one per cent YTD and about four per cent YoY.
In Q3 FY22, Sirius XM Holdings Inc noted a YoY growth of four per cent in its revenue of US$ 2.28 billion, while its net income declined to US$ 247 million from US$ 343 million in Q3 FY21.
Meanwhile, the company had raised its quarterly dividend by 10 per cent QoQ to US$ 0.0242 per share on its common stock. For fiscal 2022, the company expects its revenue to be around US$ 9 billion and its adjusted EBITDA to be about US$ 2.8 billion.
Source: ©Kalkine Media®; © Canva Creative Studio via Canva.com
Bottom line
The US market was significantly down in 2022 due to the looming concerns that have forced investors to stay on the sideline. Meanwhile, in 2021, the growth stocks were among the top-performing segment contributing most to the robust performance of the broader market.
However, several investors might be exploring opportunities in the sector, taking advantage of the beaten-down prices of the stocks.
But, keeping the continuing volatility and other uncertainties in focus, the investors should exercise due diligence before investing. The Nasdaq 100 index fell over 29 per cent YTD while increasing nearly five per cent QTD, while the Nasdaq Composite Index fell almost 30 per cent YTD while soaring about four per cent QTD.
